Capital Markets team advises on an equity fundraise to raise £9.9 million for AIM-listed, Oxford BioDynamics plc

Our Capital Markets team is advising Shore Capital (Nomad and joint broker), Northland Capital Partners (trading as Baden Hill) and WG Partners (both also as joint brokers) on a Placing, Subscriptions and PrimaryBid Offer raising £9.9 million for AIM-listed Oxford BioDynamics plc (OBD), announced by OBD on 13 March 2024. The fundraising is due to be completed in early-April 2024, following OBD shareholder approval.

Oxford BioDynamics plc is a biotechnology company developing targeted clinical diagnostic tests for immune health, based on the EpiSwitch® 3D genomics platform. The equity fundraising will provide working capital to support its on-going commercial development, through continued investment in sales and marketing activities to grow adoption of the company's global clinical, research and reference laboratory facilities – as well as licensing and partnering opportunities.

Our team was led by senior counsel Jeff Elway, supported by trainee solicitor Anna Plenderleith, and follows on from the firm advising on fundraisings for OBD in August 2023 and October 2022.

Commenting, Jeff said: "We are delighted to be advising on another fundraise for Oxford BioDynamics plc as it continues the on-going fight against cancer. We look forward to working with the parties involved together again as investors' continued belief in the value of OBD and its products drives them forward."

Gowling WLG is ranked among the top law firms for total number of stock market clients (Main Market and AIM) and have consistently been ranked as a leading AIM market adviser, both by number of clients and market capitalisation (Advisers Rankings Guide). We are particularly noted for our international experience and our comprehensive capital markets offering.